Aurobindo Pharma gets official action indicated status from USFDA; shares trade lower

The pharma major had reported 80 percent rise in consolidated net profit to Rs 909 crore in the Jan-March quarter of FY24 from Rs 508 crore in the same period a year ago.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Aurobindo Pharma share price was trading marginally lower in the early trade on May 27 after USFDA classified the company's Telangana facility as ‘Official Action Indicated (OAI)’.

At 09:28am, Aurobindo Pharma was quoting at Rs 1,228.10, down Rs 6.95, or 0.56 percent, on the BSE.

The United States Food and Drug Administration (USFDA) had conducted an inspection at Unit III, a formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the company, situated at Pashamylaram, Patancheru Mandal, Sangareddy District, Telangana, from 22nd January to 2nd February 2024.

Subsequently, the USFDA has determined the inspection classification status of this facility as ‘Official Action Indicated (OAI)’.

The pharma major had reported 80 percent rise in consolidated net profit to Rs 909 crore in the Jan-March quarter of FY24 from Rs 508 crore in the same period a year ago.

The company's consolidated revenue for the quarter grew by 19 percent to Rs 7,580 crore from Rs 6,473 crore in the same quarter a year ago.

EBITDA or Earnings Before Interest, Tax, Depreciation and Amortisation increased 68 percent year-on-year to Rs 1687 crore. EBITDA margin for the quarter expanded to 22.3 percent from 15.5 percent in the same period a year ago.

Earlier this month, USFDA in an Enforcement Report informed that Aurobindo Pharma is recalling products in the US market due to manufacturing issues.

Aurobindo Pharma is recalling 13,605 bottles of Clorazepate Dipotassium Tablets (3.75 mg and 7.5 mg), used to treat anxiety, in the American market. The company’s US-based arm is recalling the affected lot due to ”Discoloration: Dotted and yellow spots on tablets”, USFDA stated.

The USFDA stated that another drug firm FDC Ltd is recalling 3,82,104 units of Timolol Maleate Ophthalmic Solution, used to treat glaucoma, in the American market due to a”Defective Container”.

The share touched a 52-week high of Rs 1,245.60 and a 52-week low of Rs 584.55 on 24 May, 2024 and 29 May, 2023, respectively.

Currently, the stock is trading 1.4 percent below its 52-week high and 110.09 percent above its 52-week low.